Gefitinib (Iressa) is a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) kinase, but gefitinib resistance resulting from activation of STAT3 signaling has been reported to occur in cancer patients [10,11]. Here, STAT3 is linked to cancer.